Title : Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.

Pub. Date : 2018 Feb

PMID : 28971495






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Herein, we described the first report of a patient with relapsed chronic lymphocytic leukaemia harbouring TP53 abnormalities who developed, histologically proven, systemic light chain amyloidosis who was treated with the PI3K inhibitor, idelalisib, and rituximab. idelalisib tumor protein p53 Homo sapiens